{"nctId":"NCT00599027","briefTitle":"An Exploratory Study of Nasonex in Patients With Moderate to Severe Persistent Allergic Rhinitis and Intermittent Asthma","startDateStruct":{"date":"2008-05"},"conditions":["Allergic Rhinitis","Asthma"],"count":51,"armGroups":[{"label":"Mometasone furoate nasal spray","type":"EXPERIMENTAL","interventionNames":["Drug: Mometasone furoate nasal spray (MFNS)"]},{"label":"Placebo nasal spray","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo nasal spray"]}],"interventions":[{"name":"Mometasone furoate nasal spray (MFNS)","otherNames":["Nasonex Nasal Spray"]},{"name":"Placebo nasal spray","otherNames":["Placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Outpatients (≥18 and ≤ 75 years of age) of either sex\n* Willingness to participate and comply with procedures by signing a written informed consent\n* Moderate/severe persistent allergic rhinitis with a history of intermittent asthma from at least 2 years and actual asthma (symptoms in the last 4 weeks)\n* To qualify at the randomization visit the daily average of the T5SS \\[(Morning-time T5SS + Evening-time T5SS)/2\\] had to be ≥ 6 in at least 4 days during the 1 week run-in period\n* Positive (weal diameter \\>3 mm) skin prick test (SPT) and/or CAP-RAST (class II or higher) performed in the 6 months prior to the start of the trial were required for at least house dust mite and 1 pollen allergen (grass or Parietaria, IgE level \\>3.5 U/mL)\n* All prior medication washout times had been observed\n* Female volunteers of childbearing potential had to agree to use a medically accepted method of contraception or be surgically sterilized prior to screening, while receiving protocol-specified medication, and for 30 days after stopping the medication\n* Negative urine pregnancy test\n* Free of any clinically relevant disease that would have interfered with study evaluations\n* Able to adhere to the dosing and visit schedules, and agree to record symptom severity scores and use of IMP and rescue medications in a daily diary\n\nExclusion Criteria:\n\n* Female who was or intended to become pregnant during the study or within 12 weeks after study completion\n* Nursing, or intended to be nursing during the study or within 12 months after study completion\n* Taking medications prohibited during the study or had not complied with the requirements for the designated washout periods for any of the prohibited medications\n* Anatomical abnormalities of the nose (turbinate hypertrophy, septal deviation, polyps)\n* Acute or chronic sinusitis currently being treated with antibiotics and/or topical or oral decongestants\n* Rhinitis medicamentosa\n* Evidence of persistent asthma, or asthma with daytime and nighttime symptoms not controlled by short-acting beta2-adrenoceptor agonists\n* Asthma requiring chronic use of inhaled or systemic corticosteroids\n* Upper respiratory tract or sinus infection that required antibiotic therapy and had not had at least a 14-day wash-out period prior to the run-in period, or had a viral upper respiratory infection within 7 days prior to screening\n* Dependence on nasal, oral or ocular decongestants, nasal topical antihistamines, or nasal steroids\n* Undergoing a progressive course of immunotherapy (hyposensitization). Subjects on a regular maintenance schedule prior to the screening visit were eligible for study inclusion; however, subject could not receive hyposensitization treatment within 24 hours prior to any study visit\n* Diagnosed of cancer within the past 5 years (except for successfully treated basal and squamous cell carcinomas)\n* Concomitant medical problem\n* Had any of the following clinical conditions: active or quiescent tuberculosis infection of the respiratory tract, untreated fungal, bacterial, systemic viral infections or ocular herpes simplex\n* Smoked or had smoked within the previous 6 months\n* Member of the staff, affiliated with, or family member of the staff personnel directly involved with this study\n* Previously randomized into this study\n* Any other clinically significant deviation from normal in the physical examination or medical history that could interfere with the study evaluation or affect subject safety\n* In a situation or condition that could interfere with participation in the study\n* Used any drug or device in an investigational protocol in the 30 days prior to visit 1\n* Participating in other clinical studies\n* Allergic or has sensitivity to the study drug or its excipients\n* Compromised ability to provide informed consent\n* History of non-compliance with medication or treatment protocols","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Change of the Rhinasthma Global Summary Score From Baseline to Endpoint After 28 Days of Treatment.","description":"To explore the efficacy of mometasone furoate nasal spray in comparison with placebo in improving the quality of life of subjects with moderate-severe PER and intermittent asthma as measured by the Rhinasthma Questionnaire (Global Summary Score). The Rhinasthma is a questionnaire that consists of 30 items and for each of them subjects had to indicate on a Likert scale (1=not at all; 5=very much) the degree of limitation or discomfort caused by each problem. Possible total best score = 150 and possible total worst score = 30.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.3","spread":"10.03"},{"groupId":"OG001","value":"26.7","spread":"18.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.3","spread":"7.15"},{"groupId":"OG001","value":"0.4","spread":"12.32"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":26},"commonTop":[]}}}